About HealthDay | Email Editors | Email Sales  
November 20, 2009 


Related Stories

Asthma Combo Seems Less Influenced by Genes

Errors in Surgical Procedures Persist

Too Few Older Adults Get Recommended Screenings

Diuretics Still Best Treatment for High Blood Pressure

Heartburn Drugs Can Thwart Popular Blood Thinner

Web Giants Urge FDA to Update Ad Guidelines

Printer Friendly Format

FDA Warns of Skin-Numbing Drug Dangers
Popular topical anesthetics can cause severe reactions when used improperly, agency says

FRIDAY, Jan. 16 (HealthDay News) -- The U.S. Food and Drug Administration on Friday warned consumers and health-care providers about serious and life-threatening risks associated with improper use of topical anesthetics available in over-the-counter (OTC) and prescription forms.

These skin-numbing products in cremes, ointments or gels contain anesthetic drugs such as lidocaine, tetracaine, benzocaine, and prilocaine that are used to desensitize nerve endings near the skin's surface. If used improperly, the FDA said in an agency news release, the drugs can be absorbed into the bloodstream and cause reactions such as irregular heartbeat, seizures, breathing difficulties, coma or even death.

Women considering using a topical anesthetic before a mammogram should talk to their physician first, the FDA said. The agency also recommended against using these products over large areas of skin, especially irritated or broken skin, and not to wrap the treated skin with dressings or apply heat to the treated area. Raising the skin's temperature, the agency said, increases the amount of anesthetic reaching the blood stream, and its effects can be unpredictable.

The FDA said it had received several "adverse events accounts" and reports of two deaths in women who had used topical anesthetics before laser hair removal.

The agency, which had issued a public health warning in February 2007 about the drugs, urged consumers to consider using topical anesthetics that contain the lowest possible amount of medication to relieve their pain and for health care professionals to consider alternative treatments when feasible.

More information

To read the full advisory, visit the U.S. Food and Drug Administration.



-- HealthDay staff



SOURCE: U.S. Food and Drug Administration, news release, Jan. 16, 2009

Last Updated: Jan. 16, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.